Literature DB >> 22077719

Vaccines for malaria: how close are we?

Mahamadou A Thera1, Christopher V Plowe.   

Abstract

Vaccines are the most powerful public health tools mankind has created, but malaria parasites are bigger, more complicated, and wilier than the viruses and bacteria that have been conquered or controlled with vaccines. Despite decades of research toward a vaccine for malaria, this goal has remained elusive. Nevertheless, recent advances justify optimism that a licensed malaria vaccine is within reach. A subunit recombinant protein vaccine that affords in the neighborhood of 50% protective efficacy against clinical malaria is in the late stages of clinical evaluation in Africa. Incremental improvements on this successful vaccine are possible and worth pursuing, but the best hope for a highly efficacious malaria vaccine that would improve prospects for malaria eradication may lie with the use of attenuated whole parasites and powerful immune-boosting adjuvants.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22077719      PMCID: PMC3338248          DOI: 10.1146/annurev-med-022411-192402

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  62 in total

1.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

Authors:  K A Bojang; P J Milligan; M Pinder; L Vigneron; A Alloueche; K E Kester; W R Ballou; D J Conway; W H Reece; P Gothard; L Yamuah; M Delchambre; G Voss; B M Greenwood; A Hill; K P McAdam; N Tornieporth; J D Cohen; T Doherty
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

2.  Immunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium falciparum-infected erythrocytes.

Authors:  Marion Avril; Megan M Cartwright; Marianne J Hathaway; Mirja Hommel; Salenna R Elliott; Kathryn Williamson; David L Narum; Patrick E Duffy; Michal Fried; James G Beeson; Joseph D Smith
Journal:  Infect Immun       Date:  2010-03-01       Impact factor: 3.441

Review 3.  A multilateral effort to develop DNA vaccines against falciparum malaria.

Authors:  Sanjai Kumar; Judith E Epstein; Thomas L Richie; Francis K Nkrumah; Lorraine Soisson; Daniel J Carucci; Stephen L Hoffman
Journal:  Trends Parasitol       Date:  2002-03

4.  Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine.

Authors:  Amed Ouattara; Jianbing Mu; Shannon Takala-Harrison; Renion Saye; Issaka Sagara; Alassane Dicko; Amadou Niangaly; Junhui Duan; Ruth D Ellis; Louis H Miller; Xin-zhuan Su; Christopher V Plowe; Ogobara K Doumbo
Journal:  Malar J       Date:  2010-06-21       Impact factor: 2.979

5.  Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum.

Authors:  J B Dame; J L Williams; T F McCutchan; J L Weber; R A Wirtz; W T Hockmeyer; W L Maloy; J D Haynes; I Schneider; D Roberts
Journal:  Science       Date:  1984-08-10       Impact factor: 47.728

6.  Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.

Authors:  Shannon L Takala; Drissa Coulibaly; Mahamadou A Thera; Adrian H Batchelor; Michael P Cummings; Ananias A Escalante; Amed Ouattara; Karim Traoré; Amadou Niangaly; Abdoulaye A Djimdé; Ogobara K Doumbo; Christopher V Plowe
Journal:  Sci Transl Med       Date:  2009-10-14       Impact factor: 17.956

7.  Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Dapa A Diallo; Issaka Sagara; Alassane Dicko; David J Diemert; D Gray Heppner; V Ann Stewart; Evelina Angov; Lorraine Soisson; Amanda Leach; Kathryn Tucker; Kirsten E Lyke; Christopher V Plowe
Journal:  PLoS Clin Trials       Date:  2006-11-24

8.  Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.

Authors:  P J Barr; K M Green; H L Gibson; I C Bathurst; I A Quakyi; D C Kaslow
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

9.  The cysteine-rich interdomain region from the highly variable plasmodium falciparum erythrocyte membrane protein-1 exhibits a conserved structure.

Authors:  Michael M Klein; Apostolos G Gittis; Hua-Poo Su; Morris O Makobongo; Jaime M Moore; Sanjay Singh; Louis H Miller; David N Garboczi
Journal:  PLoS Pathog       Date:  2008-09-05       Impact factor: 6.823

10.  Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

Authors:  Yimin Wu; Ruth D Ellis; Donna Shaffer; Erica Fontes; Elissa M Malkin; Siddhartha Mahanty; Michael P Fay; David Narum; Kelly Rausch; Aaron P Miles; Joan Aebig; Andrew Orcutt; Olga Muratova; Guanhong Song; Lynn Lambert; Daming Zhu; Kazutoyo Miura; Carole Long; Allan Saul; Louis H Miller; Anna P Durbin
Journal:  PLoS One       Date:  2008-07-09       Impact factor: 3.240

View more
  26 in total

1.  A Plasmodium-encoded cytokine suppresses T-cell immunity during malaria.

Authors:  Tiffany Sun; Thomas Holowka; Yan Song; Swen Zierow; Lin Leng; Yibang Chen; Huabao Xiong; Jason Griffith; Mehdi Nouraie; Philip E Thuma; Elias Lolis; Chris J Janse; Victor R Gordeuk; Kevin Augustijn; Richard Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

2.  Current status of malaria vaccines.

Authors:  Deepak Gaur; Virander S Chauhan
Journal:  Indian J Pediatr       Date:  2013-04-19       Impact factor: 1.967

3.  The Jeremiah Metzger lecture: new additions to the toolbox for global malaria eradication.

Authors:  Christopher V Plowe
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

4.  Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.

Authors:  Puneet K Gupta; Paushali Mukherjee; Shikha Dhawan; Alok K Pandey; Suman Mazumdar; Deepak Gaur; S K Jain; Virander S Chauhan
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

5.  Malaria-infected mice live until at least day 30 after a new artemisinin-derived thioacetal thiocarbonate combined with mefloquine are administered together in a single, low, oral dose.

Authors:  Alexander M Jacobine; Jennifer R Mazzone; Rachel D Slack; Abhai K Tripathi; David J Sullivan; Gary H Posner
Journal:  J Med Chem       Date:  2012-08-27       Impact factor: 7.446

6.  Antimalarial chemotherapy: artemisinin-derived dimer carbonates and thiocarbonates.

Authors:  Jennifer R Mazzone; Ryan C Conyers; Abhai K Tripathi; David J Sullivan; Gary H Posner
Journal:  Bioorg Med Chem Lett       Date:  2014-04-16       Impact factor: 2.823

7.  Steps toward a globally available malaria vaccine: harnessing the potential of algae for future low cost vaccines.

Authors:  Carla S Jones; Stephen P Mayfield
Journal:  Bioengineered       Date:  2012-05-01       Impact factor: 3.269

Review 8.  Virus-Based Nanoparticles as Versatile Nanomachines.

Authors:  Kristopher J Koudelka; Andrzej S Pitek; Marianne Manchester; Nicole F Steinmetz
Journal:  Annu Rev Virol       Date:  2015-09-25       Impact factor: 10.431

9.  Antimalarial chemotherapy: orally curative artemisinin-derived trioxane dimer esters.

Authors:  Ryan C Conyers; Jennifer R Mazzone; Abhai K Tripathi; David J Sullivan; Gary H Posner
Journal:  Bioorg Med Chem Lett       Date:  2014-11-27       Impact factor: 2.823

10.  A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.

Authors:  R Mark Jones; Jessica A Chichester; Slobodanka Manceva; Sandra K Gibbs; Konstantin Musiychuk; Moneim Shamloul; Joey Norikane; Stephen J Streatfield; Marga van de Vegte-Bolmer; Will Roeffen; Robert W Sauerwein; Vidadi Yusibov
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.